Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Neurodegenerative Diseases Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Neurodegenerative Diseases Drugmarket, defines the market attractiveness level of Neurodegenerative Diseases Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Neurodegenerative Diseases Drug industry, describes the types of Neurodegenerative Diseases Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neurodegenerative Diseases Drug market and the development prospects and opportunities of Neurodegenerative Diseases Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neurodegenerative Diseases Drug market in Chapter 13.
By Player:
Biogen
Teva Pharmaceuticals
UCB SA
Lundbeck Pharmaceuticals Italy SpA
Mitsubishi Tanabe Pharma America
Orion Pharma Ltd
Novartis
Pfizer
Roche
ACADIA Pharmaceuticals Inc
Sanofi
By Type:
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
By End-User:
Multiple Sclerosis
Parkinson?s Disease
Alzheimer?s Disease
Spinal Muscular Atrophy (SMA)
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Neurodegenerative Diseases Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Neurodegenerative Diseases Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Neurodegenerative Diseases Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Neurodegenerative Diseases Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Neurodegenerative Diseases Drug Market Analysis and Outlook to 2022
-
7.1 Global Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.2 United States Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.3 Europe Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.4 China Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.5 Japan Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.6 India Neurodegenerative Diseases Drug Consumption (2017-2022)
-
7.7 South Korea Neurodegenerative Diseases Drug Consumption (2017-2022)
8 Region and Country-wise Neurodegenerative Diseases Drug Market Analysis and Outlook to 2028
-
8.1 Global Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.2 United States Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.3 Europe Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.4 China Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.5 Japan Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.6 India Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
9 Global Neurodegenerative Diseases Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Neurodegenerative Diseases Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global By Drug Class Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Immunomodulator Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Interferons Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.1.7 Global By Route of Administration Consumption and Growth Rate (2017-2022)
-
9.1.8 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.9 Global Injection Consumption and Growth Rate (2017-2022)
-
9.1.10 Global Transdermal Consumption and Growth Rate (2017-2022)
-
9.2 Global Neurodegenerative Diseases Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Parkinson?s Disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Alzheimer?s Disease Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Others Consumption and Growth Rate (2017-2022)
10 Global Neurodegenerative Diseases Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Immunomodulator Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.1.7 Global By Route of Administration Consumption Forecast and Growth Rate (2022-2028)
-
10.1.8 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
10.1.9 Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
10.1.10 Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Parkinson?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Alzheimer?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Neurodegenerative Diseases Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Neurodegenerative Diseases Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Neurodegenerative Diseases Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Neurodegenerative Diseases Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Neurodegenerative Diseases Drug Market Competitive Analysis
-
14.1 Biogen
-
14.1.1 Biogen Company Details
-
14.1.2 Biogen Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Biogen Neurodegenerative Diseases Drug Product and Service
-
14.2 Teva Pharmaceuticals
-
14.2.1 Teva Pharmaceuticals Company Details
-
14.2.2 Teva Pharmaceuticals Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Product and Service
-
14.3 UCB SA
-
14.3.1 UCB SA Company Details
-
14.3.2 UCB SA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 UCB SA Neurodegenerative Diseases Drug Product and Service
-
14.4 Lundbeck Pharmaceuticals Italy SpA
-
14.4.1 Lundbeck Pharmaceuticals Italy SpA Company Details
-
14.4.2 Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Product and Service
-
14.5 Mitsubishi Tanabe Pharma America
-
14.5.1 Mitsubishi Tanabe Pharma America Company Details
-
14.5.2 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product and Service
-
14.6 Orion Pharma Ltd
-
14.6.1 Orion Pharma Ltd Company Details
-
14.6.2 Orion Pharma Ltd Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Product and Service
-
14.7 Novartis
-
14.7.1 Novartis Company Details
-
14.7.2 Novartis Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Novartis Neurodegenerative Diseases Drug Product and Service
-
14.8 Pfizer
-
14.8.1 Pfizer Company Details
-
14.8.2 Pfizer Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Pfizer Neurodegenerative Diseases Drug Product and Service
-
14.9 Roche
-
14.9.1 Roche Company Details
-
14.9.2 Roche Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Roche Neurodegenerative Diseases Drug Product and Service
-
14.10 ACADIA Pharmaceuticals Inc
-
14.10.1 ACADIA Pharmaceuticals Inc Company Details
-
14.10.2 ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Product and Service
-
14.11 Sanofi
-
14.11.1 Sanofi Company Details
-
14.11.2 Sanofi Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Sanofi Neurodegenerative Diseases Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Neurodegenerative Diseases Drug
-
Figure Neurodegenerative Diseases Drug Picture
-
Table Global Neurodegenerative Diseases Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Neurodegenerative Diseases Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Neurodegenerative Diseases Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure United States Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure China Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure India Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global By Drug Class Consumption and Growth Rate (2017-2022)
-
Figure Global Immunomodulator Consumption and Growth Rate (2017-2022)
-
Figure Global Interferons Consumption and Growth Rate (2017-2022)
-
Figure Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global By Route of Administration Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Injection Consumption and Growth Rate (2017-2022)
-
Figure Global Transdermal Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson?s Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Alzheimer?s Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunomodulator Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global By Route of Administration Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alzheimer?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Neurodegenerative Diseases Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Neurodegenerative Diseases Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table Biogen (Foundation Year, Company Profile and etc.)
-
Table Biogen Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Neurodegenerative Diseases Drug Product and Service
-
Table Teva Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceuticals Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceuticals Neurodegenerative Diseases Drug Product and Service
-
Table UCB SA (Foundation Year, Company Profile and etc.)
-
Table UCB SA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB SA Neurodegenerative Diseases Drug Product and Service
-
Table Lundbeck Pharmaceuticals Italy SpA (Foundation Year, Company Profile and etc.)
-
Table Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Product and Service
-
Table Mitsubishi Tanabe Pharma America (Foundation Year, Company Profile and etc.)
-
Table Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product and Service
-
Table Orion Pharma Ltd (Foundation Year, Company Profile and etc.)
-
Table Orion Pharma Ltd Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Orion Pharma Ltd Neurodegenerative Diseases Drug Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Neurodegenerative Diseases Drug Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Neurodegenerative Diseases Drug Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Neurodegenerative Diseases Drug Product and Service
-
Table ACADIA Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)
-
Table ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Neurodegenerative Diseases Drug Product and Service
-
